Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +65

Is Bristol-Myers Squibb Company (BMY) the Best Cash-Rich Dividend Stock to Invest In Now?

AI-generated analysis

📈 Bristol-Myers Squibb (BMY) ranks second on a list of eight cash-rich dividend stocks recommended for investment.

💰 The company reported $12 billion in Q3 2024 revenue, representing an 8.5% increase from the prior year.

🏦 BMY holds approximately $8 billion in cash and cash equivalents as of the end of the third quarter.

💵 The stock offers a 4.44% dividend yield with a quarterly payout of $0.60 per share.

📊 Over the trailing twelve months, operating cash flow reached $15 billion and levered free cash flow hit $17.52 billion.

🔍 Hedge fund ownership increased to 70 funds in Q3 2024, with collective stakes valued at over $3.3 billion.

💊 The FDA approved Cobenfy for schizophrenia treatment in September, contributing to a nearly 6% stock surge since the start of 2024.

📉 Oncology portfolio expansion and efficient operational management drove the strong third-quarter financial performance.

🧠 Analysts note that while BMY is solid, AI stocks may offer higher returns within shorter time frames.

📅 The article was published on December 18, 2024, analyzing data through mid-December 2023 and Q3 2024.

Bullish Signals
  • BMY reported an 8.5% year-over-year revenue increase to nearly $12 billion in the third quarter of 2024.
  • The company maintains a strong cash position with approximately $8 billion in cash and cash equivalents as of late Q3 2024.
  • BMY has increased its dividend payouts for 18 consecutive years, demonstrating a long history of shareholder returns.
  • Levered free cash flow reached $17.52 billion over the trailing twelve months, providing ample flexibility for future dividends or acquisitions.
  • Hedge fund sentiment is positive, with tracked stakes growing from 61 to 70 funds in Q3 2024, totaling over $3.3 billion.
  • The stock has gained nearly 6% since the start of 2024 following FDA approval for its schizophrenia drug Cobenfy.
Risk Factors
  • The article suggests that AI stocks may offer higher returns than BMY within a shorter time frame, potentially limiting relative upside.
  • BMY ranks second on the author's list of cash-rich dividend stocks, implying other companies in the same category might be viewed as superior.
Full Analysis
Bristol-Myers Squibb (NYSE:BMY) is highlighted as a top-tier cash-rich dividend stock, ranking second on a list of eight such companies. The article notes that corporate cash reserves have reached an all-time high of $4.11 trillion in Q1 2024, driven by strong economic conditions and elevated interest rates, with many corporations earning significant interest income on these holdings. BMY reported nearly $12 billion in revenue for the third quarter of 2024, an 8.5% increase year-over-year, fueled by growth in its oncology portfolio. The company holds approximately $8 billion in cash and cash equivalents as of the end of the quarter, maintaining a robust balance sheet that supports its status as a solid dividend payer with payouts increased for 18 consecutive years. Financial metrics show BMY generated $15 billion in operating cash flow and $17.52 billion in levered free cash flow over the trailing twelve months. The stock currently offers a 4.44% dividend yield with a quarterly payout of $0.60 per share. Hedge fund interest has grown, with stakes held by 70 funds totaling over $3.3 billion as of Q3 2024. Despite its strong fundamentals and cash position, the article suggests that BMY may not offer the highest potential returns compared to AI stocks trading at low valuations. The stock has risen nearly 6% since the start of 2024 following FDA approval for its schizophrenia treatment Cobenfy, though the author maintains a preference for higher-growth sectors.